Katoh Shojiro, Obayashi Toshihiko, Ganesh Jegatheesan Saravana, Iwasaki Masaru, Preethy Senthilkumar, Abraham Samuel Jk
Edogawa Evolutionary Lab of Science, Edogawa Hospital Campus, 2-24-18, Higashi-Koiwa, Edogawa, Tokyo 133-0052, Japan.
Edogawa Hospital, 2-24-18, Higashi-Koiwa, Edogawa, Tokyo 133-0052, Japan.
Arch Acad Emerg Med. 2020 Apr 21;8(1):e54. eCollection 2020.
COronaVIrus Disease 2019 (COVID-19) is an on-going pandemic attributed to a novel virus named SARS-CoV-2. Comparing the statistics of incidence and death rates between nations reveals that there is discrepancy amongst countries in these regards, even between countries that share borders. We herein present information from the literature indicating how cross-protection against COVID-19 conferred by the encephalitis vaccine could be the reason for lower fatality rate in the countries where immunization against encephalitis is widespread or included in national programs. This may pave the way for arriving at efficient prevention strategies as well as vaccine development.
2019冠状病毒病（COVID-19）是由一种名为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的新型病毒引起的正在流行的疾病。比较各国的发病率和死亡率统计数据发现，在这些方面各国之间存在差异，即使是接壤国家之间也是如此。我们在此提供文献中的信息，表明流行性乙型脑炎疫苗对COVID-19的交叉保护作用可能是流行性乙型脑炎免疫接种普遍或纳入国家计划的国家死亡率较低的原因。这可能为制定有效的预防策略以及疫苗研发铺平道路。
